248 related articles for article (PubMed ID: 4002188)
21. [Drug surveillance: the concept, the need and methods].
Moreno González A
An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
[No Abstract] [Full Text] [Related]
22. [Comprehensive detection of severe, potentially life-threatening drug side effects].
Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
[No Abstract] [Full Text] [Related]
23. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
[No Abstract] [Full Text] [Related]
24. [Is establishment of causality in drug surveillance reliable?].
Evreux JC
Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
[No Abstract] [Full Text] [Related]
25. [Cost/benefit analysis of a regional drug surveillance center].
Mignot G; Chichmanian RM; Spreux A; Bernard G
Therapie; 1988; 43(5):377-8. PubMed ID: 3147546
[No Abstract] [Full Text] [Related]
26. With more follow-up.
Prescrire Int; 2011 Feb; 20(113):32. PubMed ID: 21488585
[No Abstract] [Full Text] [Related]
27. [30 years' spontaneous recording systems of German physicians--results and experiences].
Kimbel KH
Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
[No Abstract] [Full Text] [Related]
28. Drug-induced cancer.
Prescrire Int; 2010 Feb; 19(105):21. PubMed ID: 20455337
[No Abstract] [Full Text] [Related]
29. An adverse drug reaction reporting program.
Wasan SM; Marshall LB
Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
[No Abstract] [Full Text] [Related]
30. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
31. [Limitations of spontaneous reporting and ways of improving the quality of the data].
Boschetti C; Borghi C; Canti D; Cortellaro M
Clin Ter; 1988 Dec; 127(6):421-9. PubMed ID: 2977315
[No Abstract] [Full Text] [Related]
32. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports].
Strehl E
Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697
[No Abstract] [Full Text] [Related]
33. [Advantages of a microcomputer system in researching duplicated reports].
Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
[No Abstract] [Full Text] [Related]
34. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
35. Revised ADR report permits internal review of drug experience.
Jeffrey LP
Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
[No Abstract] [Full Text] [Related]
36. A model for the future conduct of pharmacovigilance.
Waller PC; Evans SJ
Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844
[TBL] [Abstract][Full Text] [Related]
37. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
38. [Postmarketing surveillance of drugs].
Simon P; Soubrié C
Rev Prat; 1983 Jan; 33(1-2):23-8. PubMed ID: 6823538
[No Abstract] [Full Text] [Related]
39. Drug-induced memory disorders.
Prescrire Int; 2010 Feb; 19(105):29. PubMed ID: 20455342
[No Abstract] [Full Text] [Related]
40. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
Fermont I;
Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
